© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#CROI 2007
Click Here for More Conferences
Click Here for CROI Online
HIV: The Basics
The U.N. General Assembly Hall during the High-level Meeting on HIV/AIDS.

Conferences

Transcript: The Skinny on Metabolic Complications

Peter Staley speaks with Dr. Donald Kotler, chief of gastroenterology at St. Luke’s Roosevelt Hospital in New York and a longtime researcher

CROI 2007: Conference Notes

Your CROI cheatsheet—featuring drug news, HIV’s family tree, the skinny on blood fats and more from the biggest HIV science conference.

Transcript: The Plot Thickens: HIV Treatment Challenges

Dr. Calvin Cohen discusses Kaletra vs. Sustiva, the newly infected showing HIV drug resistance, and HIVers dying from non-AIDS cancers

Diary of a Doc: On the Origins of HIV

Thoughts on the sophisticated genetic research that is providing experts with tools they need to unwrap the mystery of the origins of HIV.Â...

Study Finds Viread Advantages in Black Patients

An analysis of two Gilead-sponsored studies suggests that black HIV-positive patients have a better chances of an undetectable viral load afte...

The Plot Thickens: HIV Treatment Challenges

Dr. Calvin Cohen discusses Kaletra vs. Sustiva, the newly infected showing HIV drug resistance, and HIVers dying from non-AIDS cancers

Transcript: What’s New? Update on Experimental Agents

Dr. Cal Cohen discusses the new integrase & CCR5 inhibitors, and a new non-nuke

What’s New? Update on Experimental Agents

Dr. Cal Cohen discusses the new integrase & CCR5 inhibitors, and a new non-nuke

The Skinny on Metabolic Complications

Dr. Don Kotler discusses news from CROI about lipodystrophy, bone loss, and metabolic problems

Twice-Daily Kaletra Possibly Better for Some Patients

An ACTG study indicates that once-daily and twice-daily Kaletra are comparable in patients over 48 weeks of treatment, but also suggests that...

Baraclude Induces HIV Drug Resistance

New research concludes that hepatitis B virus (HBV) treatment Baraclude (entecavir) is active against HIV, suggesting that that the drug will...

Study Says Less Fat for Lower Lipids

While HIV meds play a role in rates of cholesterol in HIV-positive people, it also appears diets rich in fat are likely culprits as well.  

Diary of a Doc: New Strategies for HIV-Herpes Coinfection

MD turns his gaze to the recent spate of data promoting the use of anti-herpes drugs to reduce HIV transmission and disease progression.

Non-Nuke TMC-278 Comparable to Sustiva

Tibotec’s experimental NNRTI performs well in a clinical trial pitting it against standard-of-care Sustiva in treatment-naive patients. 

HIV+ Less Responsive to Lipid-Lowering Meds

Researchers have reported HIV-positive patients are less likely to benefit from lipid-lowering therapy than their HIV-negative counterparts.
Advertisement
Newsfeed
Treatment News
Features
Opinions